**INTRODUCTION**

RTX-240, an allogeneic red cell therapeutic expressing 4-1BB ligand and IL-15TP, exhibits potent in vitro and in vivo activity and a favorable preclinical safety profile.

**RESULTS AND METHODS**

1. **Objectives**
   - To assess the immuno-stimulatory activity of RTX-240 in ex vivo assays.
   - To evaluate the potential of RTX-240 to stimulate T and natural killer (NK) cell proliferation and cytokine production.
   - To investigate the in vivo effects of RTX-240 in a murine model of disease.

2. **Results**
   - **In vitro studies:** RTX-240 stimulates T and NK cell proliferation and cytokine production.
   - **In vivo studies:** RTX-240 demonstrates therapeutic efficacy in a murine cancer model.

3. **Conclusions**
   - RTX-240 has shown promise in preclinical tumor models.

**ACKNOWLEDGMENTS**

Medical writing support was provided by Benjamin Levine, PhD.

**DISCLOSURES**

All authors: employment with and equity ownership in Rubius Therapeutics.

**REFERENCES**

American Association for Cancer Research / March 29 — April 03, 2019 / Atlanta, GA